{ "instance": { "pbyi20211231_10k.htm": { "axisCustom": 0, "axisStandard": 34, "contextCount": 206, "dts": { "calculationLink": { "local": [ "pbyi-20211231_cal.xml" ] }, "definitionLink": { "local": [ "pbyi-20211231_def.xml" ] }, "inline": { "local": [ "pbyi20211231_10k.htm" ] }, "labelLink": { "local": [ "pbyi-20211231_lab.xml" ] }, "presentationLink": { "local": [ "pbyi-20211231_pre.xml" ] }, "schema": { "local": [ "pbyi-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 642, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 34, "http://www.pumabiotechnology.com/20211231": 6, "http://xbrl.sec.gov/dei/2021q4": 6, "total": 46 }, "keyCustom": 80, "keyStandard": 441, "memberCustom": 23, "memberStandard": 42, "nsprefix": "pbyi", "nsuri": "http://www.pumabiotechnology.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 2 - Significant Accounting Policies", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "shortName": "Note 2 - Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "pbyi:AccountsReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 3 - Accounts Receivable, Net", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net", "shortName": "Note 3 - Accounts Receivable, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "pbyi:AccountsReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "pbyi:PrepaidExpenseAndOtherAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 4 - Prepaid Expenses and Other", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other", "shortName": "Note 4 - Prepaid Expenses and Other", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "pbyi:PrepaidExpenseAndOtherAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 5 - Other Current Assets", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-", "shortName": "Note 5 - Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 6 - Property and Equipment", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment", "shortName": "Note 6 - Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 7 - Leases", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-", "shortName": "Note 7 - Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 8 - Intangible Assets", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets", "shortName": "Note 8 - Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 9 - Accrued Expenses", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses", "shortName": "Note 9 - Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 10 - Debt", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "shortName": "Note 10 - Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 11 - Stockholders' Deficit", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit", "shortName": "Note 11 - Stockholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets", "role": "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 12 - 401(k) Savings Plan", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-12-401k-savings-plan", "shortName": "Note 12 - 401(k) Savings Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 13 - Income Taxes", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes", "shortName": "Note 13 - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Note 14 - Commitments and Contingencies", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies", "shortName": "Note 14 - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 15 - Subsequent Events", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events", "shortName": "Note 15 - Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 2 - Significant Accounting Policies (Tables)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-tables", "shortName": "Note 2 - Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "pbyi:AccountsReceivableTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "pbyi:ScheduleOfAccountsReceivableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 3 - Accounts Receivable, Net (Tables)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-tables", "shortName": "Note 3 - Accounts Receivable, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "pbyi:AccountsReceivableTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "pbyi:ScheduleOfAccountsReceivableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "pbyi:PrepaidExpenseAndOtherAssetsTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "pbyi:PrepaidExpenseAndOtherAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 4 - Prepaid Expenses and Other (Tables)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-tables", "shortName": "Note 4 - Prepaid Expenses and Other (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "pbyi:PrepaidExpenseAndOtherAssetsTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "pbyi:PrepaidExpenseAndOtherAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 5 - Other Current Assets (Tables)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-tables", "shortName": "Note 5 - Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 6 - Property and Equipment (Tables)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-tables", "shortName": "Note 6 - Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 7 - Leases (Tables)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-tables", "shortName": "Note 7 - Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 8 - Intangible Assets (Tables)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-tables", "shortName": "Note 8 - Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 9 - Accrued Expenses (Tables)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-tables", "shortName": "Note 9 - Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note 10 - Debt (Tables)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-tables", "shortName": "Note 10 - Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note 11 - Stockholders' Deficit (Tables)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-tables", "shortName": "Note 11 - Stockholders' Deficit (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note 13 - Income Taxes (Tables)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-tables", "shortName": "Note 13 - Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note 1 - Business and Basis of Presentation (Details Textual)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-1-business-and-basis-of-presentation-details-textual", "shortName": "Note 1 - Business and Basis of Presentation (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-5", "lang": null, "name": "pbyi:CashCashEquivalentsAndMarketableSecurities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireIntangibleAssets", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note 2 - Significant Accounting Policies (Details Textual)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual", "shortName": "Note 2 - Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueRecognitionPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-01-21", "decimals": "-5", "lang": null, "name": "pbyi:SubleaseAgreementPotentialMilestonePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note 2 - Significant Accounting Policies - Potentially Dilutive Securities Not Included in Calculation Of Diluted Net Loss Per Share (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-potentially-dilutive-securities-not-included-in-calculation-of-diluted-net-loss-per-share-details", "shortName": "Note 2 - Significant Accounting Policies - Potentially Dilutive Securities Not Included in Calculation Of Diluted Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note 2 - Significant Accounting Policies - Assets Measured at Fair Value on Recurring Basis (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details", "shortName": "Note 2 - Significant Accounting Policies - Assets Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Operations", "role": "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Note 2 - Significant Accounting Policies - Summary of Cash Equivalents and Short-term Investment (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-summary-of-cash-equivalents-and-shortterm-investment-details", "shortName": "Note 2 - Significant Accounting Policies - Summary of Cash Equivalents and Short-term Investment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note 2 - Significant Accounting Policies - Inventory Balance (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-inventory-balance-details", "shortName": "Note 2 - Significant Accounting Policies - Inventory Balance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "pbyi:AccountsReceivableTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProvisionForDoubtfulAccounts", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note 3 - Accounts Receivable, Net (Details Textual)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-details-textual", "shortName": "Note 3 - Accounts Receivable, Net (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "pbyi:ScheduleOfAccountsReceivableTableTextBlock", "pbyi:AccountsReceivableTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "pbyi:TradeAccountsReceivableNetExcludingLicenseRevenueReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note 3 - Accounts Receivable, Net - Schedule of Accounts Receivable, Net (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-accounts-receivable-net-details", "shortName": "Note 3 - Accounts Receivable, Net - Schedule of Accounts Receivable, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "pbyi:ScheduleOfAccountsReceivableTableTextBlock", "pbyi:AccountsReceivableTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "pbyi:TradeAccountsReceivableNetExcludingLicenseRevenueReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "pbyi:ScheduleOfAccountsReceivableTableTextBlock", "pbyi:AccountsReceivableTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note 3 - Accounts Receivable, Net - Schedule of Allowance for Credit Losses (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-allowance-for-credit-losses-details", "shortName": "Note 3 - Accounts Receivable, Net - Schedule of Allowance for Credit Losses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "pbyi:AccountsReceivableTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "pbyi:PrepaidExpenseAndOtherAssetsTableTextBlock", "pbyi:PrepaidExpenseAndOtherAssetsTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-4", "first": true, "lang": null, "name": "pbyi:PrepaidCROServicesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note 4 - Prepaid Expenses and Other - Prepaid Expenses and Other (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details", "shortName": "Note 4 - Prepaid Expenses and Other - Prepaid Expenses and Other (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "pbyi:PrepaidExpenseAndOtherAssetsTableTextBlock", "pbyi:PrepaidExpenseAndOtherAssetsTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-4", "first": true, "lang": null, "name": "pbyi:PrepaidCROServicesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "pbyi:DepositForManufacturingCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Note 5 - Other Current Assets - Other Current Assets (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-other-current-assets-details", "shortName": "Note 5 - Other Current Assets - Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "pbyi:DepositForManufacturingCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Note 6 - Property and Equipment (Details Textual)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-details-textual", "shortName": "Note 6 - Property and Equipment (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Note 6 - Property and Equipment - Property and Equipment, Net (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-property-and-equipment-net-details", "shortName": "Note 6 - Property and Equipment - Property and Equipment, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Note 7 - Leases (Details Textual)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-details-textual", "shortName": "Note 7 - Leases (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Comprehensive Loss", "role": "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss", "shortName": "Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Note 7 - Leases - Future Minimum Lease Payments Under ASC 842 (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-under-asc-842-details", "shortName": "Note 7 - Leases - Future Minimum Lease Payments Under ASC 842 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Note 7 - Leases - Future Minimum Lease Payments to be Receive (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-to-be-receive-details", "shortName": "Note 7 - Leases - Future Minimum Lease Payments to be Receive (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "pbyi:LesseeOperatingLeasesRelatedToSupplementalCashFlowInformationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Note 7 - Leases - Supplemental Cash Flow Information Related to Leases (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-supplemental-cash-flow-information-related-to-leases-details", "shortName": "Note 7 - Leases - Supplemental Cash Flow Information Related to Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "pbyi:LesseeOperatingLeasesRelatedToSupplementalCashFlowInformationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-7", "first": true, "lang": null, "name": "us-gaap:FiniteLivedLicenseAgreementsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Note 8 - Intangible Assets - Intangible Assets, Net (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-intangible-assets-net-details", "shortName": "Note 8 - Intangible Assets - Intangible Assets, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-7", "first": true, "lang": null, "name": "us-gaap:FiniteLivedLicenseAgreementsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Note 8 - Intangible Assets - Future Amortization Expense Maturity (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-future-amortization-expense-maturity-details", "shortName": "Note 8 - Intangible Assets - Future Amortization Expense Maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-4", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "pbyi:AccruedLegalVerdictExpenseNoncurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Note 9 - Accrued Expenses (Details Textual)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-details-textual", "shortName": "Note 9 - Accrued Expenses (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-11-02", "decimals": "2", "lang": null, "name": "pbyi:RestructuringPercentageOfReductionInHeadcount", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "pbyi:AccruedLegalVerdictExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Note 9 - Accrued Expenses - Composition of Current and Long-term Accrued Expenses (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details", "shortName": "Note 9 - Accrued Expenses - Composition of Current and Long-term Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "pbyi:AccruedLegalVerdictExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfDebt", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Note 10 - Debt (Details Textual)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual", "shortName": "Note 10 - Debt (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-5", "lang": null, "name": "us-gaap:AmortizationOfFinancingCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "057 - Disclosure - Note 10 - Debt - Schedule of Long Term Debt (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-long-term-debt-details", "shortName": "Note 10 - Debt - Schedule of Long Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R59": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "058 - Disclosure - Note 10 - Debt - Schedule of Long Term Debt (Details) (Parentheticals)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-long-term-debt-details-parentheticals", "shortName": "Note 10 - Debt - Schedule of Long Term Debt (Details) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R6": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Comprehensive Loss (Parentheticals)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss-parentheticals", "shortName": "Consolidated Statements of Comprehensive Loss (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R60": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "059 - Disclosure - Note 10 - Debt - Future Minimum Principal Payments (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-future-minimum-principal-payments-details", "shortName": "Note 10 - Debt - Future Minimum Principal Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "pbyi:ScheduleOfDeferredFinancingCostsTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-4", "first": true, "lang": null, "name": "pbyi:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060 - Disclosure - Note 10 - Debt - Schedule of Debt Issuance Costs and Discounts (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-debt-issuance-costs-and-discounts-details", "shortName": "Note 10 - Debt - Schedule of Debt Issuance Costs and Discounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "pbyi:ScheduleOfDeferredFinancingCostsTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:AccumulatedAmortizationDeferredFinanceCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061 - Disclosure - Note 11 - Stockholders' Deficit (Details Textual)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual", "shortName": "Note 11 - Stockholders' Deficit (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2011-10-31", "decimals": "1", "lang": null, "name": "pbyi:OrdinarySharesOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantToAcquireCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "062 - Disclosure - Note 11 - Stockholders' Deficit - Fair Value Options Weighted-Average Assumptions (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-fair-value-options-weightedaverage-assumptions-details", "shortName": "Note 11 - Stockholders' Deficit - Fair Value Options Weighted-Average Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantToAcquireCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeAndNonemployeeStockOptionMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "063 - Disclosure - Note 11 - Stockholders' Deficit - Options Award Assumptions (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-options-award-assumptions-details", "shortName": "Note 11 - Stockholders' Deficit - Options Award Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeAndNonemployeeStockOptionMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "064 - Disclosure - Note 11 - Stockholders' Deficit - Stock-based Compensation Expense (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stockbased-compensation-expense-details", "shortName": "Note 11 - Stockholders' Deficit - Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "065 - Disclosure - Note 11 - Stockholders' Deficit - Stock Option Activity (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details", "shortName": "Note 11 - Stockholders' Deficit - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_PlanNameAxis-The2011And2017PlansMember", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "066 - Disclosure - Note 11 - Stockholders' Deficit - Stock Options Rollforward (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-options-rollforward-details", "shortName": "Note 11 - Stockholders' Deficit - Stock Options Rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "067 - Disclosure - Note 11 - Stockholders' Deficit - Restricted Stock Units (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-restricted-stock-units-details", "shortName": "Note 11 - Stockholders' Deficit - Restricted Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "068 - Disclosure - Note 12 - 401(k) Savings Plan (Details Textual)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-12-401k-savings-plan-details-textual", "shortName": "Note 12 - 401(k) Savings Plan (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Consolidated Statements of Stockholders' Deficit", "role": "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit", "shortName": "Consolidated Statements of Stockholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "069 - Disclosure - Note 13 - Income Taxes (Details Textual)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-details-textual", "shortName": "Note 13 - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "070 - Disclosure - Note 13 - Income Taxes - Schedule of Income Tax Expense (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-details", "shortName": "Note 13 - Income Taxes - Schedule of Income Tax Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "071 - Disclosure - Note 13 - Income Taxes - Schedule of Income Tax Reconciliation (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-reconciliation-details", "shortName": "Note 13 - Income Taxes - Schedule of Income Tax Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "072 - Disclosure - Note 13 - Income Taxes - Components of Net Deferred Tax Assets (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details", "shortName": "Note 13 - Income Taxes - Components of Net Deferred Tax Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "073 - Disclosure - Note 13 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-reconciliation-of-unrecognized-tax-benefits-details", "shortName": "Note 13 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2018-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-09-30", "decimals": "-5", "first": true, "lang": null, "name": "pbyi:MilestonePaymentsMaximumAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "074 - Disclosure - Note 14 - Commitments and Contingencies (Details Textual)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual", "shortName": "Note 14 - Commitments and Contingencies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "i_2021-09-30", "decimals": "-5", "first": true, "lang": null, "name": "pbyi:MilestonePaymentsMaximumAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-11-02_2021-11-02_LitigationCaseAxis-HsuVPumaBiotechnologyIncMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "075 - Disclosure - Note 15 - Subsequent Events (Details Textual)", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events-details-textual", "shortName": "Note 15 - Subsequent Events (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "007 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 1 - Business and Basis of Presentation", "role": "http://www.pumabiotechnology.com/20211231/role/statement-note-1-business-and-basis-of-presentation", "shortName": "Note 1 - Business and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pbyi20211231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 68, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r720", "r721", "r722" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r720", "r721", "r722" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r720", "r721", "r722" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r720", "r721", "r722" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r723" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss-parentheticals", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations", "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information", "http://www.pumabiotechnology.com/20211231/role/statement-note-1-business-and-basis-of-presentation", "http://www.pumabiotechnology.com/20211231/role/statement-note-1-business-and-basis-of-presentation-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-future-minimum-principal-payments-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-debt-issuance-costs-and-discounts-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-long-term-debt-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-long-term-debt-details-parentheticals", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-fair-value-options-weightedaverage-assumptions-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-options-award-assumptions-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-restricted-stock-units-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-options-rollforward-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stockbased-compensation-expense-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-12-401k-savings-plan", "http://www.pumabiotechnology.com/20211231/role/statement-note-12-401k-savings-plan-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-reconciliation-of-unrecognized-tax-benefits-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-reconciliation-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events", "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-inventory-balance-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-potentially-dilutive-securities-not-included-in-calculation-of-diluted-net-loss-per-share-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-summary-of-cash-equivalents-and-shortterm-investment-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-accounts-receivable-net-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-allowance-for-credit-losses-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other", "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-", "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-other-current-assets-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment", "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-property-and-equipment-net-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-to-be-receive-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-under-asc-842-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-supplemental-cash-flow-information-related-to-leases-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets", "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-future-amortization-expense-maturity-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-intangible-assets-net-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-tables", "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r731" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r732" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r720", "r721", "r722" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss-parentheticals", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations", "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information", "http://www.pumabiotechnology.com/20211231/role/statement-note-1-business-and-basis-of-presentation", "http://www.pumabiotechnology.com/20211231/role/statement-note-1-business-and-basis-of-presentation-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-future-minimum-principal-payments-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-debt-issuance-costs-and-discounts-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-long-term-debt-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-long-term-debt-details-parentheticals", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-fair-value-options-weightedaverage-assumptions-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-options-award-assumptions-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-restricted-stock-units-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-options-rollforward-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stockbased-compensation-expense-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-12-401k-savings-plan", "http://www.pumabiotechnology.com/20211231/role/statement-note-12-401k-savings-plan-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-reconciliation-of-unrecognized-tax-benefits-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-reconciliation-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events", "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-inventory-balance-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-potentially-dilutive-securities-not-included-in-calculation-of-diluted-net-loss-per-share-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-summary-of-cash-equivalents-and-shortterm-investment-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-accounts-receivable-net-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-allowance-for-credit-losses-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other", "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-", "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-other-current-assets-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment", "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-property-and-equipment-net-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-to-be-receive-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-under-asc-842-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-supplemental-cash-flow-information-related-to-leases-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets", "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-future-amortization-expense-maturity-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-intangible-assets-net-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-tables", "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r717" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r719" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "pbyi_AccountsReceivableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts receivable.", "label": "Accounts Receivable [Text Block]" } } }, "localname": "AccountsReceivableTextBlock", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net" ], "xbrltype": "textBlockItemType" }, "pbyi_AccruedClinicalExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents current accrued clinical expenses.", "label": "pbyi_AccruedClinicalExpensesCurrent", "terseLabel": "Accrued other clinical development" } } }, "localname": "AccruedClinicalExpensesCurrent", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "pbyi_AccruedClinicalResearchOrganizationServicesNoncurrent": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details": { "order": 1.0, "parentTag": "pbyi_AccruedLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents noncurrent accrued clinical research organization services.", "label": "pbyi_AccruedClinicalResearchOrganizationServicesNoncurrent", "terseLabel": "Accrued CRO services" } } }, "localname": "AccruedClinicalResearchOrganizationServicesNoncurrent", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "pbyi_AccruedDevelopmentCosts": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents accrued development costs.", "label": "pbyi_AccruedDevelopmentCosts", "terseLabel": "Accrued CRO services" } } }, "localname": "AccruedDevelopmentCosts", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "pbyi_AccruedInlicensedRightsCurrent": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents current accrued in-licensed rights.", "label": "Accrued in-licensed rights, current" } } }, "localname": "AccruedInlicensedRightsCurrent", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "pbyi_AccruedLegalVerdictExpenseCurrent": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents current accrued legal verdict expense.", "label": "pbyi_AccruedLegalVerdictExpenseCurrent", "terseLabel": "Accrued legal verdict expense" } } }, "localname": "AccruedLegalVerdictExpenseCurrent", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "pbyi_AccruedLegalVerdictExpenseNoncurrent": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details": { "order": 0.0, "parentTag": "pbyi_AccruedLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents noncurrent accrued legal verdict expense.", "label": "pbyi_AccruedLegalVerdictExpenseNoncurrent", "terseLabel": "Accrued Legal Verdict Expense, Noncurrent" } } }, "localname": "AccruedLegalVerdictExpenseNoncurrent", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-details-textual" ], "xbrltype": "monetaryItemType" }, "pbyi_AccruedLiabilitiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents noncurrent accrued liabilities.", "label": "Accrued expenses, long-term", "totalLabel": "Accrued Liabilities, Noncurrent" } } }, "localname": "AccruedLiabilitiesNoncurrent", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "pbyi_AccruedManufacturingCostsCurrent": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details": { "order": 10.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents current accrued manufacturing costs.", "label": "pbyi_AccruedManufacturingCostsCurrent", "terseLabel": "Accrued manufacturing costs" } } }, "localname": "AccruedManufacturingCostsCurrent", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "pbyi_AccruedProfessionalFeesLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents current accrued professional fees liability.", "label": "pbyi_AccruedProfessionalFeesLiabilityCurrent", "terseLabel": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesLiabilityCurrent", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "pbyi_AccruedVariableConsiderationCurrent": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents current accrued variable consideration.", "label": "pbyi_AccruedVariableConsiderationCurrent", "terseLabel": "Accrued variable consideration" } } }, "localname": "AccruedVariableConsiderationCurrent", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "pbyi_AreaOfLeasedProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents are of leased property.", "label": "pbyi_AreaOfLeasedProperty", "terseLabel": "Area of Leased Property (Square Foot)" } } }, "localname": "AreaOfLeasedProperty", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-details-textual" ], "xbrltype": "areaItemType" }, "pbyi_AreaOfSubleasedProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents area of subleased property.", "label": "pbyi_AreaOfSubleasedProperty", "terseLabel": "Area of Subleased Property (Square Foot)" } } }, "localname": "AreaOfSubleasedProperty", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-details-textual" ], "xbrltype": "areaItemType" }, "pbyi_AverageIncrementalBorrowingRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents average incremental borrowing rate.", "label": "pbyi_AverageIncrementalBorrowingRate", "terseLabel": "Average Incremental Borrowing Rate" } } }, "localname": "AverageIncrementalBorrowingRate", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "percentItemType" }, "pbyi_CashAndCashEquivalentsAndRestrictedCashInExcessOfInsuredLimits": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents cash and cash equivalents and restricted noncash in excess of insured limits.", "label": "pbyi_CashAndCashEquivalentsAndRestrictedCashInExcessOfInsuredLimits", "terseLabel": "Cash and Cash Equivalents, and Restricted Cash In Excess of Insured Limits" } } }, "localname": "CashAndCashEquivalentsAndRestrictedCashInExcessOfInsuredLimits", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "pbyi_CashCashEquivalentsAndMarketableSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of cash, cash equivalents and marketable securities.", "label": "pbyi_CashCashEquivalentsAndMarketableSecurities", "terseLabel": "Cash, Cash Equivalents, and Marketable Securities" } } }, "localname": "CashCashEquivalentsAndMarketableSecurities", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-1-business-and-basis-of-presentation-details-textual" ], "xbrltype": "monetaryItemType" }, "pbyi_CashCashEquivalentsAndShorttermInvestmentsFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents fair value of cash, cash equivalents and short-term investments.", "label": "Totals, fair value" } } }, "localname": "CashCashEquivalentsAndShorttermInvestmentsFairValue", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-summary-of-cash-equivalents-and-shortterm-investment-details" ], "xbrltype": "monetaryItemType" }, "pbyi_ClinicalTrialContractsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to clinical trial contracts.", "label": "Clinical Trial Contracts [Member]" } } }, "localname": "ClinicalTrialContractsMember", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "pbyi_CompensatoryDamagesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to compensatory damages.", "label": "Compensatory Damages [Member]" } } }, "localname": "CompensatoryDamagesMember", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "pbyi_Customer1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents major customer 1.", "label": "Customer 1 [Member]" } } }, "localname": "Customer1Member", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "pbyi_Customer2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents major customer 2.", "label": "Customer 2 [Member]" } } }, "localname": "Customer2Member", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "pbyi_DebtInstrumentDebtDefaultAdditionalInterestPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percent of additional interest on outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.", "label": "pbyi_DebtInstrumentDebtDefaultAdditionalInterestPercent", "terseLabel": "Debt Instrument, Debt Default, Additional Interest, Percent" } } }, "localname": "DebtInstrumentDebtDefaultAdditionalInterestPercent", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "percentItemType" }, "pbyi_DebtInstrumentPercentageOfOriginalPrincipalAmountPayableInFinalPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents percentage of original principal amount payable in final payment for debt instrument.", "label": "pbyi_DebtInstrumentPercentageOfOriginalPrincipalAmountPayableInFinalPayment", "terseLabel": "Debt instrument, Percentage of Original Principal Amount Payable in Final Payment" } } }, "localname": "DebtInstrumentPercentageOfOriginalPrincipalAmountPayableInFinalPayment", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "percentItemType" }, "pbyi_DebtInstrumentPeriodicPaymentExitPaymentPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percent exit payment made with periodic payments of debt instrument.", "label": "pbyi_DebtInstrumentPeriodicPaymentExitPaymentPercent", "terseLabel": "Debt Instrument, Periodic Payment, Exit Payment, Percent" } } }, "localname": "DebtInstrumentPeriodicPaymentExitPaymentPercent", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "percentItemType" }, "pbyi_DebtInstrumentPeriodicPaymentPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percent periodic payment for a debt instrument.", "label": "pbyi_DebtInstrumentPeriodicPaymentPercent", "terseLabel": "Debt Instrument, Periodic Payment, Percent" } } }, "localname": "DebtInstrumentPeriodicPaymentPercent", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "percentItemType" }, "pbyi_DebtInstrumentPrepaymentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents prepayment fee percentage of debt instrument.", "label": "pbyi_DebtInstrumentPrepaymentFeePercentage", "terseLabel": "Debt Instrument, Prepayment Fee Percentage" } } }, "localname": "DebtInstrumentPrepaymentFeePercentage", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "percentItemType" }, "pbyi_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsGross": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-debt-issuance-costs-and-discounts-details": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of gross unamortized debt discount (premium) and debt issuance costs.", "label": "Debt issuance costs and discounts (Athyrium Notes)", "terseLabel": "Deferred issuance costs and discounts" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsGross", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-debt-issuance-costs-and-discounts-details" ], "xbrltype": "monetaryItemType" }, "pbyi_DeferredTaxAssetLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.", "label": "pbyi_DeferredTaxAssetLeaseLiabilities", "verboseLabel": "Lease liabilities" } } }, "localname": "DeferredTaxAssetLeaseLiabilities", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "pbyi_DeferredTaxAssetsAccruedLegalVerdict": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets accrued legal verdict.", "label": "Accrued legal verdict" } } }, "localname": "DeferredTaxAssetsAccruedLegalVerdict", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "pbyi_DeferredTaxAssetsBusinessCreditCarryforward": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets business credit carryforward.", "label": "Business credit carryforwards" } } }, "localname": "DeferredTaxAssetsBusinessCreditCarryforward", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "pbyi_DeferredTaxAssetsLiabilitiesGross": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets (liabilities) before valuation allowance.", "label": "pbyi_DeferredTaxAssetsLiabilitiesGross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesGross", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "pbyi_DeferredTaxLiabilitiesAssetsInventory": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.", "label": "pbyi_DeferredTaxLiabilitiesAssetsInventory", "negatedLabel": "Inventory" } } }, "localname": "DeferredTaxLiabilitiesAssetsInventory", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "pbyi_DeferredTaxLiabilitiesLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from lease right of use asset.", "label": "pbyi_DeferredTaxLiabilitiesLeaseRightOfUseAsset", "negatedLabel": "Lease right-of-use assets" } } }, "localname": "DeferredTaxLiabilitiesLeaseRightOfUseAsset", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "pbyi_DepositForManufacturingCostsCurrent": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-other-current-assets-details": { "order": 0.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents current deposit for manufacturing costs.", "label": "Deposit for manufacturing costs" } } }, "localname": "DepositForManufacturingCostsCurrent", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-other-current-assets-details" ], "xbrltype": "monetaryItemType" }, "pbyi_EmployeeAndNonemployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents employee and nonemployee stock option.", "label": "Employee and Nonemployee Stock Option [Member]" } } }, "localname": "EmployeeAndNonemployeeStockOptionMember", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-options-award-assumptions-details" ], "xbrltype": "domainItemType" }, "pbyi_EmploymentInducementIncentiveAwardPlanTwentySeventeenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to employment inducement incentive award plan 2017.", "label": "Employment Inducement Incentive Award Plan Twenty Seventeen [Member]" } } }, "localname": "EmploymentInducementIncentiveAwardPlanTwentySeventeenMember", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual" ], "xbrltype": "domainItemType" }, "pbyi_EquityIncentivePlanTwentyElevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents equity incentive plan 2011.", "label": "Equity Incentive Plan Twenty Eleven [Member]" } } }, "localname": "EquityIncentivePlanTwentyElevenMember", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual" ], "xbrltype": "domainItemType" }, "pbyi_EshelmanVPumaBiotechnologyIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to Eshelman v. Puma Biotechnology, Inc.", "label": "Eshelman v. Puma Biotechnology, Inc. [Member]" } } }, "localname": "EshelmanVPumaBiotechnologyIncMember", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "pbyi_FinancialInstrumentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for financial instruments.", "label": "Financial Instruments [Policy Text Block]" } } }, "localname": "FinancialInstrumentsPolicyTextBlock", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "pbyi_FinitelivedIntangibleAssetExpectedAmortizationYearEight": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in eighth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "pbyi_FinitelivedIntangibleAssetExpectedAmortizationYearEight", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Eight" } } }, "localname": "FinitelivedIntangibleAssetExpectedAmortizationYearEight", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "pbyi_FinitelivedIntangibleAssetExpectedAmortizationYearNine": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in ninth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "pbyi_FinitelivedIntangibleAssetExpectedAmortizationYearNine", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Nine" } } }, "localname": "FinitelivedIntangibleAssetExpectedAmortizationYearNine", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "pbyi_FinitelivedIntangibleAssetExpectedAmortizationYearSeven": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in seventh fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "pbyi_FinitelivedIntangibleAssetExpectedAmortizationYearSeven", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Seven" } } }, "localname": "FinitelivedIntangibleAssetExpectedAmortizationYearSeven", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "pbyi_FinitelivedIntangibleAssetExpectedAmortizationYearSix": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in sixth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "pbyi_FinitelivedIntangibleAssetExpectedAmortizationYearSix", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Six" } } }, "localname": "FinitelivedIntangibleAssetExpectedAmortizationYearSix", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "pbyi_First3OfEachParticipantsContributionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents first 3% of each participants' contributions.", "label": "First 3% of Each Participant's Contributions [Member]" } } }, "localname": "First3OfEachParticipantsContributionsMember", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-12-401k-savings-plan", "http://www.pumabiotechnology.com/20211231/role/statement-note-12-401k-savings-plan-details-textual" ], "xbrltype": "domainItemType" }, "pbyi_HsuVPumaBiotechnologyIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Hsu v. Puma Biotechnology, Inc.", "label": "Hsu v. Puma Biotechnology, Inc., [Member]" } } }, "localname": "HsuVPumaBiotechnologyIncMember", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events", "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-details-textual" ], "xbrltype": "domainItemType" }, "pbyi_IncomeTaxBenefitDueToResearchAndDevelopmentTaxCredits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income tax benefit due to research and development tax credits.", "label": "pbyi_IncomeTaxBenefitDueToResearchAndDevelopmentTaxCredits", "terseLabel": "Income Tax Benefit Due to Research and Development Tax Credits" } } }, "localname": "IncomeTaxBenefitDueToResearchAndDevelopmentTaxCredits", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "pbyi_IncreaseDecreaseInPostmarketingCommitmentLiability": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents increase (decrease) in post-marketing commitment liability.", "label": "Post-marketing commitment liability" } } }, "localname": "IncreaseDecreaseInPostmarketingCommitmentLiability", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "pbyi_InstallmentPaymentsToAcquireIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "installment payments to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "pbyi_InstallmentPaymentsToAcquireIntangibleAssets", "negatedLabel": "Installment payment for purchase of intangible asset" } } }, "localname": "InstallmentPaymentsToAcquireIntangibleAssets", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "pbyi_LeaseAgreementOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents lease agreement one.", "label": "Lease Agreement One [Member]" } } }, "localname": "LeaseAgreementOneMember", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-details-textual" ], "xbrltype": "domainItemType" }, "pbyi_LeaseAgreementTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents lease agreement two.", "label": "Lease Agreement Two [Member]" } } }, "localname": "LeaseAgreementTwoMember", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-details-textual" ], "xbrltype": "domainItemType" }, "pbyi_LeaseOptionToExtendTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents lease option to extend term.", "label": "pbyi_LeaseOptionToExtendTerm", "terseLabel": "Lease Option To Extend Term (Year)" } } }, "localname": "LeaseOptionToExtendTerm", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-details-textual" ], "xbrltype": "durationItemType" }, "pbyi_LegalSettlementsPaymentsNumberOfInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents number of installments for legal settlement payments.", "label": "pbyi_LegalSettlementsPaymentsNumberOfInstallments", "terseLabel": "Legal Settlements Payments, Number of Installments" } } }, "localname": "LegalSettlementsPaymentsNumberOfInstallments", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "integerItemType" }, "pbyi_LegalVerdictExpenseCredit": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents legal verdict expense (credit).", "label": "Legal verdict expense" } } }, "localname": "LegalVerdictExpenseCredit", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "pbyi_LesseeOperatingLeasesRelatedToSupplementalCashFlowInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of operating leases related to supplemental cash flow information for lessee.", "label": "Lessee, Operating Leases Related To Supplemental Cash Flow Information [Table Text Block]" } } }, "localname": "LesseeOperatingLeasesRelatedToSupplementalCashFlowInformationTableTextBlock", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-tables" ], "xbrltype": "textBlockItemType" }, "pbyi_LicenseFeesAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for license fees and intangible assets.", "label": "License Fees and Intangible Assets [Policy Text Block]" } } }, "localname": "LicenseFeesAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "pbyi_LicenseRevenueReceivable": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-accounts-receivable-net-details": { "order": 1.0, "parentTag": "us-gaap_AccountsReceivableGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents license revenue receivable.", "label": "License revenue receivable" } } }, "localname": "LicenseRevenueReceivable", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-accounts-receivable-net-details" ], "xbrltype": "monetaryItemType" }, "pbyi_LossContingencyClaimedDamagesAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loss contingency claimed damages amount.", "label": "pbyi_LossContingencyClaimedDamagesAmount", "terseLabel": "Loss Contingency, Claimed Damages, Amount" } } }, "localname": "LossContingencyClaimedDamagesAmount", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "pbyi_LossContingencyClaimedDamagesAwardedPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss contingency claimed damages awarded per share.", "label": "pbyi_LossContingencyClaimedDamagesAwardedPerShare", "terseLabel": "Loss Contingency, Claimed Damages Awarded Per Share (in dollars per share)" } } }, "localname": "LossContingencyClaimedDamagesAwardedPerShare", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "perShareItemType" }, "pbyi_LossContingencyDamagesAwardedPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of damages awarded per share under loss contingency.", "label": "pbyi_LossContingencyDamagesAwardedPerShare", "terseLabel": "Loss Contingency, Damages Awarded Per Share (in dollars per share)" } } }, "localname": "LossContingencyDamagesAwardedPerShare", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "perShareItemType" }, "pbyi_LossContingencyDamagesAwardedPercentOfTotalClaim": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss contingency damages awarded percent of total claim.", "label": "pbyi_LossContingencyDamagesAwardedPercentOfTotalClaim", "terseLabel": "Loss Contingency, Damages Awarded Percent of Total Claim" } } }, "localname": "LossContingencyDamagesAwardedPercentOfTotalClaim", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "percentItemType" }, "pbyi_MilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents payments for milestone.", "label": "pbyi_MilestonePayment", "terseLabel": "Milestone Payment" } } }, "localname": "MilestonePayment", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "pbyi_MilestonePaymentsMaximumAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents maximum amount of milestone payments.", "label": "pbyi_MilestonePaymentsMaximumAmount", "terseLabel": "Milestone Payments Maximum Amount" } } }, "localname": "MilestonePaymentsMaximumAmount", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "pbyi_NonvestedStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents non-vested stock options.", "label": "Non-vested Stock Options [Member]" } } }, "localname": "NonvestedStockOptionsMember", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual" ], "xbrltype": "domainItemType" }, "pbyi_NotePurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to note purchase agreement.", "label": "Note Purchase Agreement [Member]" } } }, "localname": "NotePurchaseAgreementMember", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-debt-issuance-costs-and-discounts-details" ], "xbrltype": "domainItemType" }, "pbyi_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_NumberOfMajorCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc.", "label": "pbyi_NumberOfMajorCustomers", "terseLabel": "Number of Major Customers" } } }, "localname": "NumberOfMajorCustomers", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "integerItemType" }, "pbyi_NumberOfSubsidiaries": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents number of subsidiaries.", "label": "pbyi_NumberOfSubsidiaries", "terseLabel": "Number of Subsidiaries" } } }, "localname": "NumberOfSubsidiaries", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-1-business-and-basis-of-presentation-details-textual" ], "xbrltype": "integerItemType" }, "pbyi_OrdinarySharesOwnershipPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents percentage of ordinary shares ownership.", "label": "pbyi_OrdinarySharesOwnershipPercentage", "terseLabel": "Ordinary Shares Ownership Percentage" } } }, "localname": "OrdinarySharesOwnershipPercentage", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual" ], "xbrltype": "percentItemType" }, "pbyi_OxfordFinanceLimitedLiabilityCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Oxford finance limited liability company.", "label": "Oxford Finance Limited Liability Company [Member]" } } }, "localname": "OxfordFinanceLimitedLiabilityCompanyMember", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "domainItemType" }, "pbyi_PaymentForDebtExtinguishmentDebtPrepaymentCostAndOtherExtinguishmentCosts": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash outflow for debt payment, prepayment, and extinguishment costs.", "label": "pbyi_PaymentForDebtExtinguishmentDebtPrepaymentCostAndOtherExtinguishmentCosts", "negatedLabel": "Payment of prepayment costs, end of loan payment and other extinguishment costs" } } }, "localname": "PaymentForDebtExtinguishmentDebtPrepaymentCostAndOtherExtinguishmentCosts", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "pbyi_PercentageOfAnnualRentIncrement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents percentage of annual rent increment.", "label": "pbyi_PercentageOfAnnualRentIncrement", "terseLabel": "Percentage of Annual Rent Increment" } } }, "localname": "PercentageOfAnnualRentIncrement", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-details-textual" ], "xbrltype": "percentItemType" }, "pbyi_PercentageOfIssuedAndOutstandingCapitalStockOfSubsidiaryPledged": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents percentage of issued and outstanding capital stock of subsidiary pledged.", "label": "pbyi_PercentageOfIssuedAndOutstandingCapitalStockOfSubsidiaryPledged", "terseLabel": "Percentage of Issued and Outstanding Capital Stock of Subsidiary Pledged" } } }, "localname": "PercentageOfIssuedAndOutstandingCapitalStockOfSubsidiaryPledged", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "percentItemType" }, "pbyi_PercentageOfUnpaidPortionOfMilestonePaymentsInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents percentage of unpaid portion of milestone payments interest rate.", "label": "pbyi_PercentageOfUnpaidPortionOfMilestonePaymentsInterestRate", "terseLabel": "Percentage of Unpaid Portion of Milestone Payments Interest Rate" } } }, "localname": "PercentageOfUnpaidPortionOfMilestonePaymentsInterestRate", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "percentItemType" }, "pbyi_PostMarketingCommitmentLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents current post marketing commitment liability.", "label": "Post-marketing commitment liability, current" } } }, "localname": "PostMarketingCommitmentLiabilityCurrent", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "pbyi_PostmarketingCommitmentLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents noncurrent post-marketing commitment liability.", "label": "Post-marketing commitment liability, long-term" } } }, "localname": "PostmarketingCommitmentLiabilityNoncurrent", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "pbyi_PotentialMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of potential milestone payments.", "label": "pbyi_PotentialMilestonePayments", "terseLabel": "Potential Milestone Payments" } } }, "localname": "PotentialMilestonePayments", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "pbyi_PrepaidCROServicesCurrent": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents current prepaid CRO services.", "label": "CRO services" } } }, "localname": "PrepaidCROServicesCurrent", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details" ], "xbrltype": "monetaryItemType" }, "pbyi_PrepaidCROServicesNoncurrent": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details": { "order": 0.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents noncurrent prepaid CRO services.", "label": "pbyi_PrepaidCROServicesNoncurrent", "terseLabel": "CRO services" } } }, "localname": "PrepaidCROServicesNoncurrent", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details" ], "xbrltype": "monetaryItemType" }, "pbyi_PrepaidExpenseAndOtherAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of prepaid expense and other assets.", "label": "Prepaid Expense and Other Assets [TableText Block]" } } }, "localname": "PrepaidExpenseAndOtherAssetsTableTextBlock", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-tables" ], "xbrltype": "textBlockItemType" }, "pbyi_PrepaidExpenseAndOtherAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for prepaid expense and other assets.", "label": "Prepaid Expense and Other Assets [Text Block]" } } }, "localname": "PrepaidExpenseAndOtherAssetsTextBlock", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other" ], "xbrltype": "textBlockItemType" }, "pbyi_PrepaidOtherClinicalDevelopmentCurrent": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents current prepaid other clinical development.", "label": "Other clinical development" } } }, "localname": "PrepaidOtherClinicalDevelopmentCurrent", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details" ], "xbrltype": "monetaryItemType" }, "pbyi_PrepaidOtherClinicalDevelopmentExpenseNoncurrent": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents noncurrent prepaid other clinical development expense.", "label": "pbyi_PrepaidOtherClinicalDevelopmentExpenseNoncurrent", "terseLabel": "Other clinical development" } } }, "localname": "PrepaidOtherClinicalDevelopmentExpenseNoncurrent", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details" ], "xbrltype": "monetaryItemType" }, "pbyi_PrepaidProfessionalFessCurrent": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details": { "order": 0.0, "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents current prepaid professional fees.", "label": "Professional fees" } } }, "localname": "PrepaidProfessionalFessCurrent", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details" ], "xbrltype": "monetaryItemType" }, "pbyi_PunitiveDamagesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to punitive damages.", "label": "Punitive Damages [Member]" } } }, "localname": "PunitiveDamagesMember", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "pbyi_RestructuringPercentageOfReductionInHeadcount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents percentage of reduction in headcount for restructuring.", "label": "pbyi_RestructuringPercentageOfReductionInHeadcount", "terseLabel": "Restructuring, Percentage of Reduction in Headcount" } } }, "localname": "RestructuringPercentageOfReductionInHeadcount", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-details-textual" ], "xbrltype": "percentItemType" }, "pbyi_RoyaltiesPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for realities.", "label": "Royalties, Policy [Policy Text Block]" } } }, "localname": "RoyaltiesPolicyPolicyTextBlock", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "pbyi_RoyaltyRevenueReceivable": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-accounts-receivable-net-details": { "order": 2.0, "parentTag": "us-gaap_AccountsReceivableGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents information related to royalty revenue receivable.", "label": "Royalty revenue receivable" } } }, "localname": "RoyaltyRevenueReceivable", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-accounts-receivable-net-details" ], "xbrltype": "monetaryItemType" }, "pbyi_ScheduleOfAccountsReceivableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of accounts receivable.", "label": "Schedule of Accounts Receivable [Table Text Block]" } } }, "localname": "ScheduleOfAccountsReceivableTableTextBlock", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-tables" ], "xbrltype": "textBlockItemType" }, "pbyi_ScheduleOfDeferredFinancingCostsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of deferred financing costs.", "label": "Schedule of Deferred Financing Costs [Table Text Block]" } } }, "localname": "ScheduleOfDeferredFinancingCostsTableTextBlock", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-tables" ], "xbrltype": "textBlockItemType" }, "pbyi_SecondTwoPercentOfEachParticipantsContributionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents second two percent of each participants contributions.", "label": "Second Two Percent Of Each Participants Contributions [Member]" } } }, "localname": "SecondTwoPercentOfEachParticipantsContributionsMember", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-12-401k-savings-plan", "http://www.pumabiotechnology.com/20211231/role/statement-note-12-401k-savings-plan-details-textual" ], "xbrltype": "domainItemType" }, "pbyi_SecuredPromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents secured promissory notes.", "label": "Secured Promissory Notes [Member]" } } }, "localname": "SecuredPromissoryNotesMember", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "domainItemType" }, "pbyi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format.", "label": "Granted, weighted average remaining contractual term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details" ], "xbrltype": "durationItemType" }, "pbyi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsInitialContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents options initial contractual term for share-based compensation arrangement by share-based payment award.", "label": "pbyi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsInitialContractualTerm", "terseLabel": "Share-based Compensation Arrangement By Share-based Payment Award, Options Initial Contractual Term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsInitialContractualTerm", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual" ], "xbrltype": "durationItemType" }, "pbyi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award options nonvested intrinsic value.", "label": "Nonvested, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedIntrinsicValue", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details" ], "xbrltype": "monetaryItemType" }, "pbyi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award options nonvested weighted average exercise price.", "label": "Nonvested, weighted average exercise price (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "pbyi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sharebased compensation arrangement by sharebased payment award options nonvested weighted average remaining contractual term.", "label": "Nonvested, weighted average remaining contractual term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details" ], "xbrltype": "durationItemType" }, "pbyi_SiliconValleyBankAndOxfordFinanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to lenders.", "label": "Silicon Valley Bank and Oxford Finance [Member]" } } }, "localname": "SiliconValleyBankAndOxfordFinanceMember", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-debt-issuance-costs-and-discounts-details" ], "xbrltype": "domainItemType" }, "pbyi_SubleaseAgreementPotentialMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents potential milestone payments for sublease agreement.", "label": "pbyi_SubleaseAgreementPotentialMilestonePayments", "terseLabel": "Sublease Agreement, Potential Milestone Payments" } } }, "localname": "SubleaseAgreementPotentialMilestonePayments", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "pbyi_TelephoneEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to telephone equipment.", "label": "Telephone Equipment [Member]" } } }, "localname": "TelephoneEquipmentMember", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-property-and-equipment-net-details" ], "xbrltype": "domainItemType" }, "pbyi_TerminationNoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The termination notice period.", "label": "pbyi_TerminationNoticePeriod", "terseLabel": "Termination Notice Period (Day)" } } }, "localname": "TerminationNoticePeriod", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "durationItemType" }, "pbyi_The2011And2017PlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the 2011 and 2017 plans.", "label": "The 2011 and 2017 Plans [Member]" } } }, "localname": "The2011And2017PlansMember", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details" ], "xbrltype": "domainItemType" }, "pbyi_TradeAccountsReceivableNetExcludingLicenseRevenueReceivable": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-accounts-receivable-net-details": { "order": 0.0, "parentTag": "us-gaap_AccountsReceivableGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents trade accounts receivable net excluding license revenue receivable.", "label": "Trade accounts receivable" } } }, "localname": "TradeAccountsReceivableNetExcludingLicenseRevenueReceivable", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-accounts-receivable-net-details" ], "xbrltype": "monetaryItemType" }, "pbyi_UnvestedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to unvested restricted stock units.", "label": "Unvested Restricted Stock Units [Member]" } } }, "localname": "UnvestedRestrictedStockUnitsMember", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-potentially-dilutive-securities-not-included-in-calculation-of-diluted-net-loss-per-share-details" ], "xbrltype": "domainItemType" }, "pbyi_WarrantToAcquireCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents warrant to acquire common stock.", "label": "Warrant To Acquire Common Stock [Member]" } } }, "localname": "WarrantToAcquireCommonStockMember", "nsuri": "http://www.pumabiotechnology.com/20211231", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-fair-value-options-weightedaverage-assumptions-details" ], "xbrltype": "domainItemType" }, "pbyi_statement-statement-note-10-debt-future-minimum-principal-payments-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Debt - Future Minimum Principal Payments (Details)" } } }, "localname": "statement-statement-note-10-debt-future-minimum-principal-payments-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-10-debt-schedule-of-debt-issuance-costs-and-discounts-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Debt - Schedule of Debt Issuance Costs and Discounts (Details)" } } }, "localname": "statement-statement-note-10-debt-schedule-of-debt-issuance-costs-and-discounts-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-10-debt-schedule-of-long-term-debt-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Debt - Schedule of Long Term Debt (Details)" } } }, "localname": "statement-statement-note-10-debt-schedule-of-long-term-debt-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-10-debt-schedule-of-long-term-debt-details-parentheticals": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Debt - Schedule of Long Term Debt (Details) (Parentheticals)" } } }, "localname": "statement-statement-note-10-debt-schedule-of-long-term-debt-details-parentheticals", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-10-debt-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Debt" } } }, "localname": "statement-statement-note-10-debt-tables", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-11-stockholders-deficit-fair-value-options-weightedaverage-assumptions-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Stockholders' Deficit - Fair Value Options Weighted-Average Assumptions (Details)" } } }, "localname": "statement-statement-note-11-stockholders-deficit-fair-value-options-weightedaverage-assumptions-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-11-stockholders-deficit-options-award-assumptions-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Stockholders' Deficit - Options Award Assumptions (Details)" } } }, "localname": "statement-statement-note-11-stockholders-deficit-options-award-assumptions-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-11-stockholders-deficit-restricted-stock-units-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Stockholders' Deficit - Restricted Stock Units (Details)" } } }, "localname": "statement-statement-note-11-stockholders-deficit-restricted-stock-units-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-11-stockholders-deficit-stock-option-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Stockholders' Deficit - Stock Option Activity (Details)" } } }, "localname": "statement-statement-note-11-stockholders-deficit-stock-option-activity-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-11-stockholders-deficit-stock-options-rollforward-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Stockholders' Deficit - Stock Options Rollforward (Details)" } } }, "localname": "statement-statement-note-11-stockholders-deficit-stock-options-rollforward-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-11-stockholders-deficit-stockbased-compensation-expense-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Stockholders' Deficit - Stock-based Compensation Expense (Details)" } } }, "localname": "statement-statement-note-11-stockholders-deficit-stockbased-compensation-expense-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-11-stockholders-deficit-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Stockholders' Deficit" } } }, "localname": "statement-statement-note-11-stockholders-deficit-tables", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Income Taxes - Components of Net Deferred Tax Assets (Details)" } } }, "localname": "statement-statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-13-income-taxes-reconciliation-of-unrecognized-tax-benefits-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)" } } }, "localname": "statement-statement-note-13-income-taxes-reconciliation-of-unrecognized-tax-benefits-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-13-income-taxes-schedule-of-income-tax-expense-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Income Taxes - Schedule of Income Tax Expense (Details)" } } }, "localname": "statement-statement-note-13-income-taxes-schedule-of-income-tax-expense-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-13-income-taxes-schedule-of-income-tax-reconciliation-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Income Taxes - Schedule of Income Tax Reconciliation (Details)" } } }, "localname": "statement-statement-note-13-income-taxes-schedule-of-income-tax-reconciliation-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-13-income-taxes-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Income Taxes" } } }, "localname": "statement-statement-note-13-income-taxes-tables", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Significant Accounting Policies - Assets Measured at Fair Value on Recurring Basis (Details)" } } }, "localname": "statement-statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-2-significant-accounting-policies-inventory-balance-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Significant Accounting Policies - Inventory Balance (Details)" } } }, "localname": "statement-statement-note-2-significant-accounting-policies-inventory-balance-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-2-significant-accounting-policies-potentially-dilutive-securities-not-included-in-calculation-of-diluted-net-loss-per-share-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Significant Accounting Policies - Potentially Dilutive Securities Not Included in Calculation Of Diluted Net Loss Per Share (Details)" } } }, "localname": "statement-statement-note-2-significant-accounting-policies-potentially-dilutive-securities-not-included-in-calculation-of-diluted-net-loss-per-share-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-2-significant-accounting-policies-summary-of-cash-equivalents-and-shortterm-investment-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Significant Accounting Policies - Summary of Cash Equivalents and Short-term Investment (Details)" } } }, "localname": "statement-statement-note-2-significant-accounting-policies-summary-of-cash-equivalents-and-shortterm-investment-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-2-significant-accounting-policies-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Significant Accounting Policies" } } }, "localname": "statement-statement-note-2-significant-accounting-policies-tables", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-3-accounts-receivable-net-schedule-of-accounts-receivable-net-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Accounts Receivable, Net - Schedule of Accounts Receivable, Net (Details)" } } }, "localname": "statement-statement-note-3-accounts-receivable-net-schedule-of-accounts-receivable-net-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-3-accounts-receivable-net-schedule-of-allowance-for-credit-losses-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Accounts Receivable, Net - Schedule of Allowance for Credit Losses (Details)" } } }, "localname": "statement-statement-note-3-accounts-receivable-net-schedule-of-allowance-for-credit-losses-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-3-accounts-receivable-net-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Accounts Receivable, Net" } } }, "localname": "statement-statement-note-3-accounts-receivable-net-tables", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Prepaid Expenses and Other - Prepaid Expenses and Other (Details)" } } }, "localname": "statement-statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-4-prepaid-expenses-and-other-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Prepaid Expenses and Other" } } }, "localname": "statement-statement-note-4-prepaid-expenses-and-other-tables", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-5-other-current-assets-other-current-assets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Other Current Assets - Other Current Assets (Details)" } } }, "localname": "statement-statement-note-5-other-current-assets-other-current-assets-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-5-other-current-assets-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Other Current Assets" } } }, "localname": "statement-statement-note-5-other-current-assets-tables", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-6-property-and-equipment-property-and-equipment-net-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Property and Equipment - Property and Equipment, Net (Details)" } } }, "localname": "statement-statement-note-6-property-and-equipment-property-and-equipment-net-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-6-property-and-equipment-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Property and Equipment" } } }, "localname": "statement-statement-note-6-property-and-equipment-tables", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-7-leases-future-minimum-lease-payments-to-be-receive-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Leases - Future Minimum Lease Payments to be Receive (Details)" } } }, "localname": "statement-statement-note-7-leases-future-minimum-lease-payments-to-be-receive-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-7-leases-future-minimum-lease-payments-under-asc-842-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Leases - Future Minimum Lease Payments Under ASC 842 (Details)" } } }, "localname": "statement-statement-note-7-leases-future-minimum-lease-payments-under-asc-842-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-7-leases-supplemental-cash-flow-information-related-to-leases-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Leases - Supplemental Cash Flow Information Related to Leases (Details)" } } }, "localname": "statement-statement-note-7-leases-supplemental-cash-flow-information-related-to-leases-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-7-leases-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Leases" } } }, "localname": "statement-statement-note-7-leases-tables", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-8-intangible-assets-future-amortization-expense-maturity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Intangible Assets - Future Amortization Expense Maturity (Details)" } } }, "localname": "statement-statement-note-8-intangible-assets-future-amortization-expense-maturity-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-8-intangible-assets-intangible-assets-net-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Intangible Assets - Intangible Assets, Net (Details)" } } }, "localname": "statement-statement-note-8-intangible-assets-intangible-assets-net-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-8-intangible-assets-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Intangible Assets" } } }, "localname": "statement-statement-note-8-intangible-assets-tables", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Accrued Expenses - Composition of Current and Long-term Accrued Expenses (Details)" } } }, "localname": "statement-statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-note-9-accrued-expenses-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Accrued Expenses" } } }, "localname": "statement-statement-note-9-accrued-expenses-tables", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "pbyi_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://www.pumabiotechnology.com/20211231", "xbrltype": "stringItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r69", "r71", "r140", "r141", "r310", "r347" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events", "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-details-textual" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events", "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-details-textual" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r209", "r366", "r369", "r669" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r309", "r346", "r441", "r446", "r597", "r598", "r599", "r600", "r601", "r602", "r621", "r666", "r670", "r714", "r715" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r309", "r346", "r441", "r446", "r597", "r598", "r599", "r600", "r601", "r602", "r621", "r666", "r670", "r714", "r715" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r209", "r366", "r369", "r669" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r206", "r366", "r367", "r624", "r665", "r667" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r206", "r366", "r367", "r624", "r665", "r667" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r309", "r346", "r396", "r441", "r446", "r597", "r598", "r599", "r600", "r601", "r602", "r621", "r666", "r670", "r714", "r715" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r309", "r346", "r396", "r441", "r446", "r597", "r598", "r599", "r600", "r601", "r602", "r621", "r666", "r670", "r714", "r715" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r70", "r71", "r140", "r141", "r310", "r347" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "domainItemType" }, "srt_RestatementAdjustmentMember": { "auth_ref": [ "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r152", "r154", "r155", "r157", "r158", "r168", "r541", "r542" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Adjustment [Member]" } } }, "localname": "RestatementAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r1", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r154", "r155", "r156", "r157", "r158", "r159", "r168", "r228", "r229", "r486", "r522", "r540", "r541", "r542", "r543", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r733", "r734" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r1", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r154", "r155", "r156", "r157", "r158", "r159", "r168", "r228", "r229", "r486", "r522", "r540", "r541", "r542", "r543", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r733", "r734" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r1", "r144", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r154", "r155", "r157", "r158", "r168", "r228", "r229", "r486", "r522", "r540", "r541", "r542", "r543", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r733", "r734" ], "lang": { "en-us": { "role": { "label": "Previously Reported [Member]" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r207", "r208", "r366", "r368", "r668", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-details-textual" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r207", "r208", "r366", "r368", "r668", "r697", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-details-textual" ], "xbrltype": "stringItemType" }, "stpr_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CALIFORNIA" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r50", "r587" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]" } } }, "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsReceivableGross": { "auth_ref": [ "r210" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-accounts-receivable-net-details": { "order": 0.0, "parentTag": "us-gaap_AccountsReceivableNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "us-gaap_AccountsReceivableGross", "totalLabel": "Total accounts receivable" } } }, "localname": "AccountsReceivableGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-accounts-receivable-net-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r31", "r649", "r699" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-accounts-receivable-net-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "us-gaap_AccountsReceivableNet", "totalLabel": "Total accounts receivable, net" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-accounts-receivable-net-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r7", "r31", "r210", "r211" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net of allowance for credit loss of $0 and $1,000" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r16", "r17", "r56" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccruedBonusesCurrent", "terseLabel": "Accrued bonus" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r56" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses, current", "totalLabel": "Total, long-term" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r635", "r659" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.", "label": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent", "totalLabel": "Totals" } } }, "localname": "AccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r16", "r17", "r56" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details": { "order": 8.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccruedProfessionalFeesCurrent", "terseLabel": "Accrued legal fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r16", "r17", "r56" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details": { "order": 9.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccruedRoyaltiesCurrent", "terseLabel": "Accrued royalties" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedAmortizationDeferredFinanceCosts": { "auth_ref": [ "r49", "r567" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-debt-issuance-costs-and-discounts-details": { "order": 0.0, "parentTag": "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated amortization of debt issuance costs.", "label": "us-gaap_AccumulatedAmortizationDeferredFinanceCosts", "negatedLabel": "Less: accumulated amortization" } } }, "localname": "AccumulatedAmortizationDeferredFinanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-debt-issuance-costs-and-discounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r48", "r263" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-property-and-equipment-net-details": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-property-and-equipment-net-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r34", "r75", "r77", "r78", "r654", "r676", "r680" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r74", "r78", "r87", "r88", "r89", "r144", "r145", "r146", "r536", "r671", "r672", "r734" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r32" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r144", "r145", "r146", "r483", "r484", "r485", "r541" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r448", "r450", "r489", "r490" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r450", "r479", "r488" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stockbased-compensation-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r212", "r230", "r232", "r236" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-accounts-receivable-net-details": { "order": 1.0, "parentTag": "us-gaap_AccountsReceivableNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable", "negatedLabel": "Allowance for credit losses", "negatedPeriodStartLabel": "Balance", "periodEndLabel": "Balance" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-accounts-receivable-net-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-allowance-for-credit-losses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r38", "r212", "r230" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance for credit loss" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": { "auth_ref": [ "r235" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery.", "label": "Recoveries", "negatedLabel": "Provision for credit loss recovery", "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Recovery" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-allowance-for-credit-losses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r234" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Accounts receivable written-off" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-allowance-for-credit-losses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r96", "r119", "r329", "r567" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "us-gaap_AmortizationOfFinancingCosts", "terseLabel": "Amortization of Debt Issuance Costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r119", "r253", "r257" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "us-gaap_AmortizationOfIntangibleAssets", "terseLabel": "Amortization of Intangible Assets, Total" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Anti-dilutive securities not included in calculation of diluted net loss per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-potentially-dilutive-securities-not-included-in-calculation-of-diluted-net-loss-per-share-details" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-potentially-dilutive-securities-not-included-in-calculation-of-diluted-net-loss-per-share-details" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-potentially-dilutive-securities-not-included-in-calculation-of-diluted-net-loss-per-share-details" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r119", "r260" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Loss on impairment of asset" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r136", "r189", "r198", "r204", "r226", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r533", "r537", "r555", "r585", "r587", "r629", "r651" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r11", "r13", "r68", "r136", "r226", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r533", "r537", "r555", "r585", "r587" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r544" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Totals" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r218" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Unrealized gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-summary-of-cash-equivalents-and-shortterm-investment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r219" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "negatedLabel": "Unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-summary-of-cash-equivalents-and-shortterm-investment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r216", "r241" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Investments, amortized cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-summary-of-cash-equivalents-and-shortterm-investment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r214", "r217", "r241", "r634" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Investments, fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-summary-of-cash-equivalents-and-shortterm-investment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r451", "r481" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-options-award-assumptions-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-restricted-stock-units-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stockbased-compensation-expense-details" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r4", "r143", "r183" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-1-business-and-basis-of-presentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r124", "r125", "r126" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Property and equipment purchases in accounts payable" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r45", "r121" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-summary-of-cash-equivalents-and-shortterm-investment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-summary-of-cash-equivalents-and-shortterm-investment-details" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r20", "r122" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r20", "r122", "r627" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Totals, amortized cost" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-summary-of-cash-equivalents-and-shortterm-investment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r113", "r121", "r127" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r113", "r556" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-summary-of-cash-equivalents-and-shortterm-investment-details" ], "xbrltype": "domainItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosures of non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r363", "r449" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-fair-value-options-weightedaverage-assumptions-details" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-fair-value-options-weightedaverage-assumptions-details" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-summary-of-cash-equivalents-and-shortterm-investment-details" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r62", "r277", "r636", "r658" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 14)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r274", "r275", "r276", "r289", "r701" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance", "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r144", "r145", "r541" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)", "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r30", "r360" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r30", "r587" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock - $.0001 par value per share; 100,000,000 shares authorized; 41,175,507 shares issued and outstanding at December 31, 2021 and 40,086,387 issued and outstanding at December 31, 2020" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r370", "r373", "r447", "r492" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans [Text Block]" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-12-401k-savings-plan" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r82", "r84", "r85", "r93", "r639", "r661" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-property-and-equipment-net-details" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r178", "r179", "r209", "r553", "r554", "r700" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r178", "r179", "r209", "r553", "r554", "r681", "r700" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r178", "r179", "r209", "r553", "r554", "r681", "r700" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r174", "r646" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r178", "r179", "r209", "r553", "r554" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "us-gaap_ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r178", "r179", "r209", "r553", "r554", "r700" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r129", "r535" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractualObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "us-gaap_ContractualObligation", "terseLabel": "Contractual Obligation, Total" } } }, "localname": "ContractualObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-summary-of-cash-equivalents-and-shortterm-investment-details" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r98", "r624" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r97" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "us-gaap_CostsAndExpenses", "totalLabel": "Total operating costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r137", "r517", "r525" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-details": { "order": 0.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r137", "r517" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-details": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r137", "r517", "r525", "r526" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-details": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "us-gaap_CurrentIncomeTaxExpenseBenefit", "totalLabel": "Current Income Tax Expense (Benefit), Total" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r137", "r517", "r525" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-details": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r177", "r209" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDefaultLongtermDebtAmount": { "auth_ref": [ "r133" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.", "label": "us-gaap_DebtDefaultLongtermDebtAmount", "terseLabel": "Debt Instrument, Debt Default, Amount" } } }, "localname": "DebtDefaultLongtermDebtAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r133", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r323", "r330", "r331", "r333", "r344" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r24", "r25", "r26", "r135", "r142", "r306", "r307", "r308", "r309", "r310", "r311", "r313", "r319", "r320", "r321", "r322", "r324", "r325", "r326", "r327", "r328", "r329", "r338", "r339", "r340", "r341", "r568", "r630", "r632", "r648" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r26", "r334", "r632", "r648" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Total debt, inclusive of $2.0 million exit payment" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-long-term-debt-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r306", "r338", "r339", "r566", "r568", "r569" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r58", "r337", "r566", "r568" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "us-gaap_DebtInstrumentInterestRateEffectivePercentage", "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r58", "r307" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r60", "r135", "r142", "r306", "r307", "r308", "r309", "r310", "r311", "r313", "r319", "r320", "r321", "r322", "r324", "r325", "r326", "r327", "r328", "r329", "r338", "r339", "r340", "r341", "r568" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r645" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r645" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "auth_ref": [ "r645" ], "lang": { "en-us": { "role": { "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period One [Member]" } } }, "localname": "DebtInstrumentRedemptionPeriodOneMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": { "auth_ref": [ "r645" ], "lang": { "en-us": { "role": { "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Three [Member]" } } }, "localname": "DebtInstrumentRedemptionPeriodThreeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "auth_ref": [ "r645" ], "lang": { "en-us": { "role": { "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Two [Member]" } } }, "localname": "DebtInstrumentRedemptionPeriodTwoMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r319", "r565", "r569" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "us-gaap_DebtInstrumentUnamortizedDiscount", "terseLabel": "Debt Instrument, Unamortized Discount, Total" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r319", "r335", "r338", "r339", "r567" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-debt-issuance-costs-and-discounts-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "negatedLabel": "Less: deferred issuance costs and discounts", "totalLabel": "Included in long-term debt" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-debt-issuance-costs-and-discounts-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-long-term-debt-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": { "auth_ref": [ "r59" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.", "label": "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount", "terseLabel": "Debt Instrument, Unused Borrowing Capacity, Amount" } } }, "localname": "DebtInstrumentUnusedBorrowingCapacityAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r137", "r518", "r525" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-details": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredFederalIncomeTaxExpenseBenefit", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r567" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "us-gaap_DeferredFinanceCostsGross", "terseLabel": "Debt Issuance Costs, Gross" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r27", "r28", "r507", "r631", "r647" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details": { "order": 0.0, "parentTag": "pbyi_DeferredTaxAssetsLiabilitiesGross", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "us-gaap_DeferredIncomeTaxLiabilities", "negatedTotalLabel": "Subtotal" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r137", "r518", "r525" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-details": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetInterestCarryforward": { "auth_ref": [ "r515" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.", "label": "Carryforward of disallowed interest" } } }, "localname": "DeferredTaxAssetInterestCarryforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r508" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details": { "order": 1.0, "parentTag": "pbyi_DeferredTaxAssetsLiabilitiesGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsGross", "totalLabel": "Subtotal" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r510" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r515", "r516" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r515", "r516" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Other deferred tax assets" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "auth_ref": [ "r515", "r516" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.", "label": "Compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r515", "r516" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "verboseLabel": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r509" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r515", "r516" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "us-gaap_DeferredTaxLiabilitiesOther", "negatedLabel": "Other deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r435" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "us-gaap_DefinedContributionPlanCostRecognized", "terseLabel": "Defined Contribution Plan, Cost" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-12-401k-savings-plan-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent", "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-12-401k-savings-plan-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r119", "r261" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "us-gaap_Depreciation", "terseLabel": "Depreciation, Total" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r119", "r261" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-1-business-and-basis-of-presentation", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-12-401k-savings-plan", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies", "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net", "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other", "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-", "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-", "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses" ], "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r94", "r149", "r150", "r152", "r153", "r154", "r160", "r161", "r163", "r164", "r165", "r168", "r169", "r542", "r543", "r640", "r662" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss applicable to common stockholders (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r166", "r167" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "auth_ref": [ "r491", "r498" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "terseLabel": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r56" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "terseLabel": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r480" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stockbased-compensation-expense-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-potentially-dilutive-securities-not-included-in-calculation-of-diluted-net-loss-per-share-details" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r87", "r88", "r89", "r144", "r145", "r146", "r148", "r155", "r158", "r171", "r227", "r360", "r362", "r483", "r484", "r485", "r521", "r522", "r541", "r557", "r558", "r559", "r560", "r561", "r562", "r671", "r672", "r673", "r734" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtGainLossNetOfTax": { "auth_ref": [ "r342" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between the reacquisition price and the net carrying amount of the extinguished debt recognized currently as a component of income in the period of extinguishment, net of tax.", "label": "Loss on debt extinguishment" } } }, "localname": "ExtinguishmentOfDebtGainLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r544", "r545" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r321", "r338", "r339", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r433", "r545", "r594", "r595", "r596" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r544", "r545", "r547", "r548", "r550" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r321", "r397", "r398", "r403", "r433", "r545", "r594" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r321", "r338", "r339", "r397", "r398", "r403", "r433", "r545", "r595" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r321", "r338", "r339", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r433", "r545", "r596" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r321", "r338", "r339", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r433", "r594", "r595", "r596" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r549", "r550" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r551", "r552" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r220", "r221", "r223", "r224", "r225", "r231", "r237", "r238", "r239", "r240", "r242", "r243", "r244", "r245", "r332", "r358", "r539", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r724", "r725", "r726", "r727", "r728", "r729", "r730" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-tables" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r256" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-intangible-assets-net-details": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization", "negatedLabel": "Less: accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-intangible-assets-net-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-future-amortization-expense-maturity-details": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-future-amortization-expense-maturity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r258" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-future-amortization-expense-maturity-details": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year One" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-future-amortization-expense-maturity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r258" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-future-amortization-expense-maturity-details": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Five" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-future-amortization-expense-maturity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r258" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-future-amortization-expense-maturity-details": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Four" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-future-amortization-expense-maturity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r258" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-future-amortization-expense-maturity-details": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Three" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-future-amortization-expense-maturity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r258" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-future-amortization-expense-maturity-details": { "order": 0.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Two" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-future-amortization-expense-maturity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r256", "r625" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-future-amortization-expense-maturity-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsNet", "totalLabel": "Totals" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-future-amortization-expense-maturity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedLicenseAgreementsGross": { "auth_ref": [ "r256" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-intangible-assets-net-details": { "order": 0.0, "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life.", "label": "Acquired and in-licensed rights" } } }, "localname": "FiniteLivedLicenseAgreementsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-intangible-assets-net-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-property-and-equipment-net-details" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r119" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment", "negatedLabel": "Disposal of property and equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r119", "r342", "r343" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "us-gaap_GainsLossesOnExtinguishmentOfDebt", "negatedLabel": "Loss on debt extinguishment" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r91", "r189", "r197", "r200", "r203", "r205", "r626", "r637", "r642", "r663" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.", "label": "Net loss per share of common stock\u2014basic and diluted (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r265", "r269" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stockbased-compensation-expense-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stockbased-compensation-expense-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r138", "r499", "r505", "r512", "r523", "r527", "r529", "r530", "r531" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r139", "r157", "r158", "r188", "r497", "r524", "r528", "r664" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-reconciliation-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_IncomeTaxExpenseBenefit", "negatedLabel": "Income tax expense", "totalLabel": "Total provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r86", "r495", "r496", "r505", "r506", "r511", "r519" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r498" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-reconciliation-details": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r498" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-reconciliation-details": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "terseLabel": "Foreign taxes" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r498" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-reconciliation-details": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Tax computed at the federal statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "auth_ref": [ "r498" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-reconciliation-details": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Permanent items" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": { "auth_ref": [ "r498" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-reconciliation-details": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).", "label": "Prior year adjustment" } } }, "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r498" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-reconciliation-details": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes", "terseLabel": "State taxes" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "auth_ref": [ "r498" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-reconciliation-details": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "us-gaap_IncomeTaxReconciliationTaxCreditsResearch", "negatedLabel": "R&D credits" } } }, "localname": "IncomeTaxReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r115", "r123" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income taxes paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r118" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r118" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r118" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Accrued expenses and other" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r118" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventory, net" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r118" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "us-gaap_IncreaseDecreaseInOtherCurrentAssets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "auth_ref": [ "r118" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.", "label": "us-gaap_IncreaseDecreaseInPrepaidExpensesOther", "negatedLabel": "Prepaid expenses and other" } } }, "localname": "IncreaseDecreaseInPrepaidExpensesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-intangible-assets-net-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.", "label": "Intangible assets, net", "totalLabel": "Total intangible asset, net" } } }, "localname": "IntangibleAssetsNetIncludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets", "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-intangible-assets-net-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r90", "r187", "r564", "r567", "r641" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "us-gaap_InterestExpense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r112", "r114", "r123" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r39", "r248" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-inventory-balance-details": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Finished goods (materials, labor and overhead)" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-inventory-balance-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r6", "r65", "r587" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-inventory-balance-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, net", "totalLabel": "Total Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-inventory-balance-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r19", "r66", "r130", "r170", "r246", "r247", "r249", "r622" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r41", "r248" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-inventory-balance-details": { "order": 0.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-inventory-balance-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r40", "r248" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-inventory-balance-details": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Work-in-process (materials, labor and overhead)" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-inventory-balance-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r100", "r186" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-summary-of-cash-equivalents-and-shortterm-investment-details" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-summary-of-cash-equivalents-and-shortterm-investment-details" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r544" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-property-and-equipment-net-details" ], "xbrltype": "domainItemType" }, "us-gaap_LegalCostsPolicyTextBlock": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.", "label": "Legal Costs, Policy [Policy Text Block]" } } }, "localname": "LegalCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r575" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r581" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-under-asc-842-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-under-asc-842-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r581" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-under-asc-842-details": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-under-asc-842-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r581" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-under-asc-842-details": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-under-asc-842-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r581" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-under-asc-842-details": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-under-asc-842-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r581" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-under-asc-842-details": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-under-asc-842-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r581" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-under-asc-842-details": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-under-asc-842-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r581" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-under-asc-842-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r583" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r584" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-to-be-receive-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payments to be received by lessor for operating lease.", "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "totalLabel": "Total" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-to-be-receive-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": { "auth_ref": [ "r584" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-to-be-receive-details": { "order": 4.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears", "terseLabel": "2026" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-to-be-receive-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "auth_ref": [ "r584" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-to-be-receive-details": { "order": 3.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears", "terseLabel": "2025" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-to-be-receive-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.", "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "auth_ref": [ "r584" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-to-be-receive-details": { "order": 0.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "terseLabel": "2022" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-to-be-receive-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "auth_ref": [ "r584" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-to-be-receive-details": { "order": 2.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears", "terseLabel": "2024" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-to-be-receive-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "auth_ref": [ "r584" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-to-be-receive-details": { "order": 1.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears", "terseLabel": "2023" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-to-be-receive-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "us-gaap_LettersOfCreditOutstandingAmount", "terseLabel": "Letters of Credit Outstanding, Amount" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r54", "r136", "r199", "r226", "r295", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r534", "r537", "r538", "r555", "r585", "r586" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r37", "r136", "r226", "r555", "r587", "r633", "r656" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and stockholders' deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r57", "r136", "r226", "r295", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r534", "r537", "r538", "r555", "r585", "r586", "r587" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r52", "r135" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-debt-issuance-costs-and-discounts-details" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r52", "r135" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-debt-issuance-costs-and-discounts-details" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r52" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "us-gaap_LitigationSettlementAmountAwardedToOtherParty", "terseLabel": "Litigation Settlement, Amount Awarded to Other Party" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "us-gaap_LitigationSettlementExpense", "terseLabel": "Litigation Settlement, Expense" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r26", "r320", "r336", "r338", "r339", "r632", "r652" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-future-minimum-principal-payments-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "us-gaap_LongTermDebt", "terseLabel": "Long-term Debt, Total", "totalLabel": "Total" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-future-minimum-principal-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r142", "r293", "r325" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-future-minimum-principal-payments-details": { "order": 0.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "verboseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-future-minimum-principal-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r142", "r293", "r325" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-future-minimum-principal-payments-details": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "verboseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-future-minimum-principal-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r142", "r293", "r325" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-future-minimum-principal-payments-details": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "verboseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-future-minimum-principal-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r142", "r293", "r325" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-future-minimum-principal-payments-details": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "verboseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-future-minimum-principal-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r142", "r293", "r325" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-future-minimum-principal-payments-details": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "verboseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-future-minimum-principal-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r60" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Total long-term debt, net" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-long-term-debt-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r60", "r294" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r277", "r278", "r279", "r282", "r283", "r284", "r287", "r290", "r291" ], "lang": { "en-us": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in loss contingency liability.", "label": "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease", "terseLabel": "Loss Contingency Accrual, Period Increase (Decrease), Total" } } }, "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesAwardedValue": { "auth_ref": [ "r277", "r280", "r285" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of damages awarded to the plaintiff in the legal matter.", "label": "us-gaap_LossContingencyDamagesAwardedValue", "terseLabel": "Loss Contingency, Damages Awarded, Value" } } }, "localname": "LossContingencyDamagesAwardedValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r277", "r280", "r285" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "us-gaap_LossContingencyDamagesSoughtValue", "terseLabel": "Loss Contingency, Damages Sought, Value" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyEstimateOfPossibleLoss": { "auth_ref": [ "r281", "r286", "r290" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.", "label": "us-gaap_LossContingencyEstimateOfPossibleLoss", "terseLabel": "Loss Contingency, Estimate of Possible Loss" } } }, "localname": "LossContingencyEstimateOfPossibleLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r277", "r278", "r279", "r282", "r283", "r284", "r287", "r290", "r291" ], "lang": { "en-us": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r8", "r55" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r643" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-fair-value-options-weightedaverage-assumptions-details" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-fair-value-options-weightedaverage-assumptions-details" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-fair-value-options-weightedaverage-assumptions-details" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-fair-value-options-weightedaverage-assumptions-details" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-fair-value-options-weightedaverage-assumptions-details" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-fair-value-options-weightedaverage-assumptions-details" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r113" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r113" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "terseLabel": "Net Cash Provided by (Used in) Investing Activities, Total", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r113", "r117", "r120" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "terseLabel": "Net Cash Provided by (Used in) Operating Activities, Total", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-", "http://www.pumabiotechnology.com/20211231/role/statement-note-1-business-and-basis-of-presentation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r3", "r81", "r83", "r89", "r92", "r120", "r136", "r147", "r149", "r150", "r152", "r153", "r157", "r158", "r162", "r189", "r197", "r200", "r203", "r205", "r226", "r295", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r543", "r555", "r638", "r660" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "terseLabel": "Net Income (Loss) Attributable to Parent, Total", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-1-business-and-basis-of-presentation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": { "auth_ref": [ "r124", "r125", "r126" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Intangibles in accrued expenses" } } }, "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r101" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total other expenses" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expenses):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating costs and expenses:" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r189", "r197", "r200", "r203", "r205" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Income (1oss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r573" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "us-gaap_OperatingLeaseExpense", "terseLabel": "Operating Lease, Expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseImpairmentLoss": { "auth_ref": [ "r570" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.", "label": "us-gaap_OperatingLeaseImpairmentLoss", "terseLabel": "Operating Lease, Impairment Loss" } } }, "localname": "OperatingLeaseImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r572" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-under-asc-842-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r572" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Lease liabilities, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r572" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Lease liabilities, long-term" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r574", "r577" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating cash flows used for operating leases (in thousands)" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-supplemental-cash-flow-information-related-to-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r571" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Lease right-of-use assets, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r580", "r582" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-supplemental-cash-flow-information-related-to-leases-details" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r579", "r582" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining lease term (in years) (Year)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-supplemental-cash-flow-information-related-to-leases-details" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r513" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_OperatingLossCarryforwards", "terseLabel": "Operating Loss Carryforwards, Total" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r16", "r17", "r18", "r56" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "us-gaap_OtherAccruedLiabilitiesCurrent", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesNoncurrent": { "auth_ref": [ "r61" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details": { "order": 2.0, "parentTag": "pbyi_AccruedLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.", "label": "us-gaap_OtherAccruedLiabilitiesNoncurrent", "terseLabel": "Accrued other" } } }, "localname": "OtherAccruedLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r67", "r587" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-other-current-assets-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other current assets", "totalLabel": "Totals" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets", "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-other-current-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMiscellaneousCurrent": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-other-current-assets-details": { "order": 1.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.", "label": "Other" } } }, "localname": "OtherAssetsMiscellaneousCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-other-current-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive (loss) income:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": { "auth_ref": [ "r75", "r79", "r80", "r222" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.", "label": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "negatedLabel": "Reclassifications of gain on available-for-sale securities, included in \u201cOther income (expenses),\" net of tax of $0, $0, and $0" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax": { "auth_ref": [ "r76", "r222" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.", "label": "Reclassifications of gain on available-for-sale securities, included in \u201cOther income (expense)\u201d, tax" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss-parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r72", "r75" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Unrealized (loss) gain on available-for-sale securities, net of tax of $0, $0, and $0" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": { "auth_ref": [ "r73", "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Unrealized loss on available-for-sale securities, tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss-parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other current assets.", "label": "Other Current Assets [Text Block]" } } }, "localname": "OtherCurrentAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r102" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r9", "r12", "r252" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "us-gaap_OtherPrepaidExpenseCurrent", "terseLabel": "Other" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForLegalSettlements": { "auth_ref": [ "r116" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.", "label": "us-gaap_PaymentsForLegalSettlements", "terseLabel": "Payments for Legal Settlements" } } }, "localname": "PaymentsForLegalSettlements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "auth_ref": [ "r111" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.", "label": "Exit payment" } } }, "localname": "PaymentsOfDebtExtinguishmentCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-long-term-debt-details-parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r110" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "us-gaap_PaymentsOfDebtIssuanceCosts", "negatedLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r103", "r105", "r215" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt", "negatedLabel": "Purchase of available-for-sale securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r106" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "us-gaap_PaymentsToAcquireIntangibleAssets", "negatedLabel": "Purchase of intangible assets", "terseLabel": "Payments to Acquire Intangible Assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r106" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r451", "r481" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.", "label": "us-gaap_PrepaidExpenseAndOtherAssets", "totalLabel": "Totals" } } }, "localname": "PrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": { "auth_ref": [ "r23", "r628", "r650" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other, long-term", "totalLabel": "Prepaid Expense and Other Assets, Noncurrent" } } }, "localname": "PrepaidExpenseAndOtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets", "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r9", "r12", "r251", "r252" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details": { "order": 0.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses, current", "totalLabel": "Total, long-term" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets", "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseOtherNoncurrent": { "auth_ref": [ "r15", "r49" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.", "label": "us-gaap_PrepaidExpenseOtherNoncurrent", "verboseLabel": "Other" } } }, "localname": "PrepaidExpenseOtherNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r10", "r12", "r250", "r252" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r108" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from debt", "terseLabel": "Proceeds from Issuance of Debt" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r107", "r482" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Net proceeds from shares issued under employee stock plans" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r108", "r135" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "us-gaap_ProceedsFromLinesOfCredit", "terseLabel": "Proceeds from Lines of Credit, Total" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r103", "r104", "r215" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Maturity of available-for-sale securities" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r103", "r104", "r215" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Sale of available-for-sale securities" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r48", "r264" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-property-and-equipment-net-details" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r266", "r702", "r703", "r704" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r47", "r262" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-property-and-equipment-net-details": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-property-and-equipment-net-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r21", "r22", "r264", "r587", "r644", "r657" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-property-and-equipment-net-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "totalLabel": "Totals" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets", "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-property-and-equipment-net-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r46", "r264", "r702", "r703" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r21", "r264" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r21", "r262" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-property-and-equipment-net-details" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, Plant and Equipment, Useful Life (Year)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r95", "r233" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Provision for credit loss expense", "terseLabel": "Accounts Receivable, Credit Loss Expense (Reversal)" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-allowance-for-credit-losses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r109" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "us-gaap_RepaymentsOfDebt", "negatedLabel": "Payment of debt", "terseLabel": "Repayments of Debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r493", "r623", "r716" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stockbased-compensation-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r127", "r627", "r653" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "us-gaap_RestrictedCash", "terseLabel": "Restricted Cash, Total" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-summary-of-cash-equivalents-and-shortterm-investment-details" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r5", "r20", "r127" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted cash, current" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r14", "r23", "r127", "r698" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted cash, long-term" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-restricted-stock-units-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stockbased-compensation-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": { "auth_ref": [ "r267", "r270", "r271", "r273" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of costs incurred to date for the specified restructuring cost.", "label": "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1", "terseLabel": "Restructuring and Related Cost, Cost Incurred to Date" } } }, "localname": "RestructuringAndRelatedCostCostIncurredToDate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r267", "r268", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r33", "r362", "r486", "r587", "r655", "r675", "r680" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r144", "r145", "r146", "r148", "r155", "r158", "r227", "r483", "r484", "r485", "r521", "r522", "r541", "r671", "r673" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r371", "r372", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r442", "r443", "r444", "r445" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-12-401k-savings-plan", "http://www.pumabiotechnology.com/20211231/role/statement-note-12-401k-savings-plan-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r371", "r372", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r442", "r443", "r444", "r445" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-12-401k-savings-plan", "http://www.pumabiotechnology.com/20211231/role/statement-note-12-401k-savings-plan-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r184", "r185", "r196", "r201", "r202", "r206", "r207", "r209", "r365", "r366", "r624" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Total revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r131", "r132" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r578", "r582" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-use assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-supplemental-cash-flow-information-related-to-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r178", "r209" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, Cash Equivalents and Investments [Table Text Block]" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r498" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r450", "r478", "r488" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r254", "r255" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r19", "r42", "r43", "r44" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other current assets.", "label": "Schedule of Other Current Assets [Table Text Block]" } } }, "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r462", "r467", "r470" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r472" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r504", "r520" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r190", "r191", "r192", "r193", "r194", "r195", "r207" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r99" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stockbased-compensation-expense-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r118" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensation", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedTerseLabel": "Forfeited shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-restricted-stock-units-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "terseLabel": "Forfeited, Weighted Average Grant-Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-restricted-stock-units-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "terseLabel": "Granted shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-restricted-stock-units-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)", "verboseLabel": "Granted, Weighted Average Grant-Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-restricted-stock-units-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodEndLabel": "Nonvested shares (in shares)", "periodStartLabel": "Nonvested shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-restricted-stock-units-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodEndLabel": "Nonvested, Beginning balance, Weighted Average Grant-Date Fair Value (in dollars per share)", "periodStartLabel": "Nonvested, Beginning balance, Weighted Average Grant-Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-restricted-stock-units-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedTerseLabel": "Vested/Issued shares (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-restricted-stock-units-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Vested/Issued, Weighted Average Grant-Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-restricted-stock-units-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-options-award-assumptions-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-options-award-assumptions-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-options-award-assumptions-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Exercisable, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Exercisable, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r469" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Exercised, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "negatedLabel": "Expired, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Forfeited, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-options-rollforward-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Granted, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-options-rollforward-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Granted, Weighted Average Grant-Date Fair Value (in dollars per share)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-options-rollforward-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r481" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Outstanding, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r457", "r481" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodEndLabel": "Balance, shares (in shares)", "periodStartLabel": "Balance, shares (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Balance, weighted average exercise price (in dollars per share)", "periodStartLabel": "Balance, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r449", "r453" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-options-award-assumptions-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-restricted-stock-units-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stockbased-compensation-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercised, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Expired, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Forfeited, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Granted, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r451", "r454" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r473", "r487" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected life in years (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-options-award-assumptions-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r481" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Exercisable, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Exercisable, weighted average remaining contractual term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Nonvested, shares (in shares)", "periodEndLabel": "Nonvested shares (in shares)", "periodStartLabel": "Nonvested shares (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-options-rollforward-details" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options forfeited.", "label": "ForfeitedForfeited, Weighted Average Grant-Date Fair Value (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-options-rollforward-details" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "periodEndLabel": "Nonvested, Beginning balance, Weighted Average Grant-Date Fair Value (in dollars per share)", "periodStartLabel": "Nonvested, Beginning balance, Weighted Average Grant-Date Fair Value (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-options-rollforward-details" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Outstanding, weighted average remaining contractual term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "negatedLabel": "Vested/Issued, shares (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-options-rollforward-details" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Vested/Issued, Weighted Average Grant-Date Fair Value (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-options-rollforward-details" ], "xbrltype": "perShareItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r128", "r143" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r64", "r87", "r88", "r89", "r144", "r145", "r146", "r148", "r155", "r158", "r171", "r227", "r360", "r362", "r483", "r484", "r485", "r521", "r522", "r541", "r557", "r558", "r559", "r560", "r561", "r562", "r671", "r672", "r673", "r734" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss-parentheticals", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-1-business-and-basis-of-presentation", "http://www.pumabiotechnology.com/20211231/role/statement-note-1-business-and-basis-of-presentation-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-future-minimum-principal-payments-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-debt-issuance-costs-and-discounts-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-long-term-debt-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-long-term-debt-details-parentheticals", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-fair-value-options-weightedaverage-assumptions-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-options-award-assumptions-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-restricted-stock-units-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-options-rollforward-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stockbased-compensation-expense-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-12-401k-savings-plan", "http://www.pumabiotechnology.com/20211231/role/statement-note-12-401k-savings-plan-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-reconciliation-of-unrecognized-tax-benefits-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-reconciliation-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events", "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-inventory-balance-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-potentially-dilutive-securities-not-included-in-calculation-of-diluted-net-loss-per-share-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-summary-of-cash-equivalents-and-shortterm-investment-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-accounts-receivable-net-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-allowance-for-credit-losses-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other", "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-", "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-other-current-assets-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment", "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-property-and-equipment-net-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-to-be-receive-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-under-asc-842-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-supplemental-cash-flow-information-related-to-leases-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets", "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-future-amortization-expense-maturity-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-intangible-assets-net-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-tables", "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r144", "r145", "r146", "r171", "r624" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss-parentheticals", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-1-business-and-basis-of-presentation", "http://www.pumabiotechnology.com/20211231/role/statement-note-1-business-and-basis-of-presentation-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-future-minimum-principal-payments-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-debt-issuance-costs-and-discounts-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-long-term-debt-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-schedule-of-long-term-debt-details-parentheticals", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-fair-value-options-weightedaverage-assumptions-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-options-award-assumptions-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-restricted-stock-units-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-options-rollforward-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stockbased-compensation-expense-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-12-401k-savings-plan", "http://www.pumabiotechnology.com/20211231/role/statement-note-12-401k-savings-plan-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-components-of-net-deferred-tax-assets-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-reconciliation-of-unrecognized-tax-benefits-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-expense-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-schedule-of-income-tax-reconciliation-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events", "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-inventory-balance-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-potentially-dilutive-securities-not-included-in-calculation-of-diluted-net-loss-per-share-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-summary-of-cash-equivalents-and-shortterm-investment-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-accounts-receivable-net-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-schedule-of-allowance-for-credit-losses-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other", "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-", "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-other-current-assets-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment", "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-property-and-equipment-net-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-to-be-receive-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-future-minimum-lease-payments-under-asc-842-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-supplemental-cash-flow-information-related-to-leases-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets", "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-future-amortization-expense-maturity-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-intangible-assets-net-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-tables", "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r29", "r30", "r360", "r362" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Shares issued or restricted stock units vested under employee stock plans (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r29", "r30", "r360", "r362", "r459" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised", "negatedLabel": "Exercised, shares (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r29", "r30", "r360", "r362" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Shares issued or restricted stock units vested under employee stock plans" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r30", "r35", "r36", "r136", "r213", "r226", "r555", "r587" ], "calculation": { "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets", "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r134", "r345", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r359", "r362", "r364" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r576", "r582" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "us-gaap_SubleaseIncome", "terseLabel": "Sublease Income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r563", "r589" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events", "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r563", "r589" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events", "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r563", "r589" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events", "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r588", "r590" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-15-subsequent-events" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-3-accounts-receivable-net-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-4-prepaid-expenses-and-other-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-5-other-current-assets-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-6-property-and-equipment-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-8-intangible-assets-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r513" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_TaxCreditCarryforwardAmount", "terseLabel": "Tax Credit Carryforward, Amount" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r220", "r221", "r223", "r224", "r225", "r332", "r358", "r539", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r724", "r725", "r726", "r727", "r728", "r729", "r730" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-tables" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies", "http://www.pumabiotechnology.com/20211231/role/statement-note-14-commitments-and-contingencies-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-", "http://www.pumabiotechnology.com/20211231/role/statement-note-7-leases-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r267", "r268", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses", "http://www.pumabiotechnology.com/20211231/role/statement-note-9-accrued-expenses-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r494", "r501" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "us-gaap_UnrecognizedTaxBenefits", "periodEndLabel": "Unrecognized tax benefits - December 31", "periodStartLabel": "Unrecognized tax benefits - January 1" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-reconciliation-of-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r502" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "negatedLabel": "Gross decreases - tax positions in a prior period" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-reconciliation-of-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r503" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Gross increases - tax positions in a current period", "terseLabel": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-details-textual", "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-reconciliation-of-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r172", "r173", "r175", "r176", "r180", "r181", "r182" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r510" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount", "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-13-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-", "http://www.pumabiotechnology.com/20211231/role/statement-note-10-debt-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-tables", "http://www.pumabiotechnology.com/20211231/role/statement-note-2-significant-accounting-policies-potentially-dilutive-securities-not-included-in-calculation-of-diluted-net-loss-per-share-details" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrant measurement Input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-note-11-stockholders-deficit-fair-value-options-weightedaverage-assumptions-details" ], "xbrltype": "decimalItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted-average shares of common stock outstanding\u2014basic and diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.pumabiotechnology.com/20211231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r143": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r249": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r259": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r266": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r276": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751" }, "r289": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r344": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r364": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r373": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r447": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944" }, "r492": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r531": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r583": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123366838&loc=d3e3073-115593" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r717": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r718": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r719": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r720": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r721": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r722": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r723": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r724": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r725": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r726": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r727": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r728": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r729": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r730": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r731": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r732": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" } }, "version": "2.1" }